Capsida Receives FDA IND Clearance for Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy
CAP-002 is the first engineered IV-delivered gene therapy that crosses the blood-brain-barrier and detargets the liver and dorsal root ganglia to enter the clinic... Read more.
Genascence Phase 1b DONATELLO Trial Evaluating Potential First-in-Class Gene Therapy for Knee Osteoarthritis (OA) Meets Primary Endpoint Showing GNSC-001 Was Safe and Well Tolerated Across Multiple Dosing Arms
Expression of the therapeutic gene, IL-1Ra, was sustained out to 12-month timepoint, reaching target levels GNSC-001 is designed to offer long-term, sustained IL-1... Read more.
MITER Brands Celebrates Team Member Awarded Florida Apprentice of the Year
NORTH VENICE, Fla.–(BUSINESS WIRE)–MITER Brands, a residential window and door manufacturer, recently celebrated team member Andrew Clark, who was bestowed... Read more.
Chegg Reports 2025 First Quarter Earnings
Makes progress on strategic alternatives process and initiates additional restructuring of the business SANTA CLARA, Calif.–(BUSINESS WIRE)–Chegg, Inc.... Read more.
SelectQuote, Inc. Reports Third Quarter of Fiscal Year 2025 Results
Third Quarter of Fiscal Year 2025 – Consolidated Earnings Highlights Revenue of $408.2 million Net income of $26.0 million Adjusted EBITDA* of $37.7 million Fiscal... Read more.
Agenus Reports Q1 2025 Financial Results and Key Business Updates
BOT/BAL Achieves Breakthrough Response Rates in MSS Cancers — Oral AACR Data Spotlight Pan-Tumor Neoadjuvant Success Seasoned Leader Onboard to Accelerate BOT/BAL... Read more.
Entegris Announces CEO Succession Plan
Bertrand Loy to Retire After 13 Years as President and CEO in August 2025; Will Continue to Serve as Executive Chair of the Entegris Board of Directors David Reeder... Read more.
Chewy CFO David Reeder to Depart Chewy, Company Reaffirms First Quarter Guidance
PLANTATION, Fla.–(BUSINESS WIRE)–Chewy, Inc. (NYSE: CHWY), a trusted destination for pet parents and partners everywhere, announced today that the Company’s... Read more.
IonQ to Present at The Economist Impact’s Commercialising Quantum Global 2025 Event
IonQ’s Dr. Dean Kassmann will discuss recent company advancements in quantum computing, networking and applications COLLEGE PARK, Md.–(BUSINESS WIRE)–IonQ... Read more.
Circle Pharma to Present Trials in Progress Poster on CID-078, a First-in-Class Cyclin A/B Inhibitor, at the ASCO 2025 Annual Meeting
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–#ASCO2025–Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics... Read more.